MedTrace Logo

Pre-Operative Single Shot Rectus Sheath Block

NCT03458598 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2022-07-28

No results posted yet for this study

Summary

Objectives The primary objective is to demonstrate that in patients undergoing major urologic surgery, Patient Controlled Analgesia (PCA) opioid consumption in the first 24 hours after surgery will be significantly less in patients who have had a single shot rectus sheath block pre-operatively in addition to a post-operative rectus sheath continuous block via surgically placed catheter versus those who only have post-operative rectus sheath continuous block. Secondary outcomes will be opioid requirement intra-operatively, Numerical Rating Scale (NRS) pain scores including maximum pain score in Post Anesthesia Care Unit (PACU) and score at 24 and 48 hours, incidence and severity of nausea, number of vomiting episodes, sedation score, time to first bowel movement, time to first mobilization and duration of hospital stay.

Conditions

  • Bladder Neoplasm
  • Prostate Neoplasm
  • Pelvic Neoplasm
  • Urologic Neoplasms
  • Opioid Use
  • Anesthesia, Local
  • Pain, Postoperative

Interventions

PROCEDURE

Rectus sheath block

Rectus sheath block under ultrasound

PROCEDURE

Bilateral rectus sheath catheter

A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.

DRUG

Patient controlled opioid analgesia (PCA)

Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.

PROCEDURE

Subcutaneous injection saline placebo

Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-16
Primary Completion
2019-02-05
Completion
2019-02-05

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03458598 on ClinicalTrials.gov